BR0012443A - Lipolìmero neutro e composições de lipossoma contendo o mesmo - Google Patents

Lipolìmero neutro e composições de lipossoma contendo o mesmo

Info

Publication number
BR0012443A
BR0012443A BR0012443-5A BR0012443A BR0012443A BR 0012443 A BR0012443 A BR 0012443A BR 0012443 A BR0012443 A BR 0012443A BR 0012443 A BR0012443 A BR 0012443A
Authority
BR
Brazil
Prior art keywords
neutral
lipopolymers
liposomes
lipolymer
compositions containing
Prior art date
Application number
BR0012443-5A
Other languages
English (en)
Inventor
Samuel Zalipsky
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of BR0012443A publication Critical patent/BR0012443A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00Applications
    • C08L2203/02Applications for biomedical use
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyethers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Patente de Invenção: "LIPOLìMERO NEUTRO E COMPOSIçõES DE LIPOSSOMA CONTENDO O MESMO". Lipossomas contendo lipopolímeros neutros substituídos por PEG fornecem tempos de circulação similares os lipossomas que incorporam fosfolipídeos substituídos por PEG negativamente carregados convencionais. O uso dos lipopolímeros não carregados pode também apresentar vantagens em termos de interações com as superfícies celulares e vazamento reduzido de substâncias carregadas, particularmente drogas catiónicas, dos lipossomas. Os lipopolímeros são da fórmula (1) em que cada um de R^ 1^ e R^ 2^ é uma cadeia de alquila ou alquenila tendo entre cerca de 8 a cerca de 24 átomos de carbono; n é de cerca de 10 a cerca de 300, Z é selecionado do grupo que consiste em hidróxi, alcóxi, benzilóxi, éster carboxílico, éster suifónico, carbamato de alquila ou de arila, amino e alquilamino e a ligação L é selecionada do grupo que consiste em (i) -X-(C=O)-Y-CH~ 2~-, (ii) X-(C=O)- e (iii) -X-CH~ 2~-, em que X e Y são independentemente selecionados de oxigênio, NH, e uma ligação direta.
BR0012443-5A 1999-07-14 2000-07-12 Lipolìmero neutro e composições de lipossoma contendo o mesmo BR0012443A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14381099P 1999-07-14 1999-07-14
PCT/US2000/018949 WO2001005873A1 (en) 1999-07-14 2000-07-12 Neutral lipopolymer and liposomal compositions containing same

Publications (1)

Publication Number Publication Date
BR0012443A true BR0012443A (pt) 2002-04-02

Family

ID=22505748

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0012443-5A BR0012443A (pt) 1999-07-14 2000-07-12 Lipolìmero neutro e composições de lipossoma contendo o mesmo

Country Status (24)

Country Link
US (1) US6586001B1 (pt)
EP (1) EP1198490B1 (pt)
JP (1) JP2003505401A (pt)
KR (2) KR100758158B1 (pt)
CN (1) CN1193059C (pt)
AT (1) ATE317869T1 (pt)
AU (1) AU769517B2 (pt)
BR (1) BR0012443A (pt)
CA (1) CA2379060A1 (pt)
CY (1) CY1105466T1 (pt)
CZ (1) CZ2002140A3 (pt)
DE (1) DE60026030T2 (pt)
DK (1) DK1198490T3 (pt)
ES (1) ES2255501T3 (pt)
HK (1) HK1048484B (pt)
HU (1) HUP0202177A3 (pt)
IL (2) IL147564A0 (pt)
MX (1) MXPA02000402A (pt)
NO (1) NO20020175L (pt)
PL (1) PL352711A1 (pt)
PT (1) PT1198490E (pt)
RU (1) RU2250911C2 (pt)
WO (1) WO2001005873A1 (pt)
ZA (1) ZA200200303B (pt)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1347743T3 (da) * 2000-12-07 2006-07-03 Univ Utrecht Holding Bv Præparat til behandling af inflammatoriske lidelser
US20030077829A1 (en) * 2001-04-30 2003-04-24 Protiva Biotherapeutics Inc.. Lipid-based formulations
AU2003238929A1 (en) 2002-06-07 2003-12-22 Rutgers, The State University Micelle assemblies
CA2491164C (en) 2002-06-28 2012-05-08 Cory Giesbrecht Method and apparatus for producing liposomes
JP2006519262A (ja) * 2003-02-28 2006-08-24 アルザ・コーポレーシヨン リポソームにより誘導される補体活性化の減少のためのリポソーム組成物
CN100379404C (zh) * 2003-02-28 2008-04-09 阿尔扎公司 用于减少脂质体诱导的补体激活的脂质体组合物
US20060198882A1 (en) * 2003-03-21 2006-09-07 Yechezkel Barenholz Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
MXPA05010926A (es) * 2003-04-15 2005-11-25 Opperbas Holding Bv Composicion farmaceutica que comprende proteinas y/o polipeptidos y particulas coloidales.
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
CA2510040C (en) * 2003-05-23 2012-01-03 Nektar Therapeutics Al, Corporation Polymeric reagents and polymer-biomolecule conjugates comprising carbamate linkages
KR20060015265A (ko) * 2003-05-30 2006-02-16 알자 코포레이션 제제의 폐 투여 방법
CA2532228C (en) * 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
NZ592917A (en) * 2003-09-15 2012-12-21 Protiva Biotherapeutics Inc Stable polyethyleneglycol (PEG) dialkyloxypropyl (DAA) lipid conjugates
CA2542804A1 (en) * 2003-10-24 2005-05-06 Alza Corporation Preparation of lipid particles
US20050191344A1 (en) * 2004-01-15 2005-09-01 Samuel Zalipsky Liposome composition for delivery of therapeutic agents
JP4796062B2 (ja) 2004-06-07 2011-10-19 プロチバ バイオセラピューティクス インコーポレイティッド 脂質封入干渉rna
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
CA2587470A1 (en) * 2004-11-15 2006-05-18 Yissum Research Development Company Of The Hebrew University Of Jerusale M Combination therapy associating preferably a ceramide with a cytotoxic drug
WO2007005754A2 (en) * 2005-07-01 2007-01-11 Alza Corporation Liposomal delivery vehicle for hydrophobic drugs
US20070055199A1 (en) 2005-08-10 2007-03-08 Gilbert Scott J Drug delivery device for buccal and aural applications and other areas of the body difficult to access
ES2611924T3 (es) * 2006-10-03 2017-05-11 Arbutus Biopharma Corporation Formulaciones que contienen lípidos
CN101583380B (zh) * 2006-11-30 2013-07-10 尼克塔治疗公司 用于制备聚合物轭合物的方法
US8466255B2 (en) 2007-02-05 2013-06-18 Nippon Shinyaku Co., Ltd. Polyethylene glycol derivative
JP5415283B2 (ja) 2007-02-07 2014-02-12 グラダリス インク. シアル酸産生を調節し、遺伝性封入体ミオパチーを治療する方法及び組成物
US20110097720A1 (en) * 2008-01-02 2011-04-28 Alnylam Pharmaceuticals, Inc. Screening method for selected amino lipid-containing compositions
DK2279254T3 (en) 2008-04-15 2017-09-18 Protiva Biotherapeutics Inc PRESENT UNKNOWN LIPID FORMS FOR NUCLEIC ACID ADMINISTRATION
KR100967833B1 (ko) 2008-05-20 2010-07-05 아이디비켐(주) 고순도의 폴리에틸렌글리콜 알데하이드 유도체의 제조방법
US9173840B2 (en) 2008-10-09 2015-11-03 Northeastern University Multifunctional self-assembling polymeric nanosystems
CN102439151A (zh) 2009-03-19 2012-05-02 默沙东公司 使用短干扰核酸(siNA)的RNA干扰介导的BTB和CNC同系物1,碱性亮氨酸拉链转录因子1(Bach1)基因表达的抑制
EP2408458A1 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520685A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸(siNA)を用いたGATA結合タンパク質3(GATA3)遺伝子発現のRNA干渉媒介性阻害
US20120016011A1 (en) 2009-03-19 2012-01-19 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
WO2010111497A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE INTERCELLULAR ADHESION MOLECULE 1 (ICAM-1)GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012521764A (ja) 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸(siNA)を用いた胸腺間質性リンパ球新生因子(TSLP)遺伝子発現のRNA干渉媒介性阻害
EP2411019A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2011000106A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Improved cationic lipids and methods for the delivery of therapeutic agents
EP2449114B9 (en) 2009-07-01 2017-04-19 Protiva Biotherapeutics Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
JP5605760B2 (ja) * 2010-01-18 2014-10-15 セイコーエプソン株式会社 吐出用液体、生体試料の吐出方法、及び化合物
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
WO2012027206A1 (en) 2010-08-24 2012-03-01 Merck Sharp & Dohme Corp. SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
EP2609106A4 (en) 2010-08-26 2014-03-19 Merck Sharp & Dohme RNA INTERFERENCE-MEDIATED INHIBITION OF EXPRESSION OF PHD2 GENE (PROLYL HYDROXYLASE DOMAIN 2) USING SMALL INTERFERING NUCLEIC ACID (PANI)
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
DK3202760T3 (da) * 2011-01-11 2019-11-25 Alnylam Pharmaceuticals Inc Pegylerede lipider og deres anvendelse til lægemiddelfremføring
US8846850B2 (en) 2011-02-22 2014-09-30 Rutgers, The State University Of New Jersey Amphiphilic macromolecules for nucleic acid delivery
JP5949036B2 (ja) * 2011-03-29 2016-07-06 日油株式会社 ポリオキシアルキレン修飾脂質およびその製造方法
US8575380B2 (en) 2011-10-17 2013-11-05 Nof Corporation Branched polyethylene glycol linked with diacyl glycerol, process for producing the same, and polyethylene glycol modified liposome
EP2861558B1 (en) 2012-06-15 2017-01-18 Rutgers, The State University of New Jersey Macromolecules for treating atherosclerosis
US10138203B2 (en) 2014-06-16 2018-11-27 Rutgers, The State University Of New Jersey Antibacterial agents
US9630905B2 (en) 2014-09-08 2017-04-25 Rutgers, The State University Of New Jersey Amphiphilic macromolecules and methods of use thereof
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
US10759740B2 (en) 2016-03-24 2020-09-01 Rutgers, The State University Of New Jersey Antibacterial agents
US10640725B2 (en) 2016-08-05 2020-05-05 Rutgers, The State University Of New Jersey Thermocleavable friction modifiers and methods thereof
JP2023553343A (ja) 2020-11-25 2023-12-21 アカゲラ・メディスンズ,インコーポレイテッド 核酸を送達するための脂質ナノ粒子および関連する使用方法
GB202111757D0 (en) 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111758D0 (en) 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles for use in the treatment of haemophilia A
GB202111759D0 (en) 2021-08-17 2021-09-29 Cantab Biopharmaceuticals Patents Ltd Modified colloidal particles
CA3234809A1 (en) 2021-10-20 2023-04-27 Steven Goldman Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2694893A1 (fr) * 1992-08-03 1994-02-25 Oreal Composition formée d'une dispersion aqueuse de vésicules de lipides amphiphiles non-ioniques stabilisées.
US5741518A (en) * 1992-08-03 1998-04-21 L'oreal Composition composed of an aqueous dispersion of stabilized vesicles of nonionic amphiphilic lipids
WO1995025764A1 (fr) * 1994-03-23 1995-09-28 Meiji Seika Kabushiki Kaisha Derive bicatenaire de lipide contenant un polyoxyethylene
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
PT957929E (pt) * 1996-10-25 2006-06-30 Gilead Sciences Inc Complexos de ligandos de acido nucleico do factor de crescimento endotelial vascular

Also Published As

Publication number Publication date
CY1105466T1 (el) 2010-04-28
IL147564A (en) 2007-03-08
KR20020012008A (ko) 2002-02-09
HK1048484B (zh) 2005-10-14
CN1193059C (zh) 2005-03-16
US6586001B1 (en) 2003-07-01
DE60026030T2 (de) 2006-08-10
CN1360611A (zh) 2002-07-24
CZ2002140A3 (cs) 2002-05-15
JP2003505401A (ja) 2003-02-12
HUP0202177A3 (en) 2004-05-28
RU2250911C2 (ru) 2005-04-27
IL147564A0 (en) 2002-08-14
MXPA02000402A (es) 2002-07-30
CA2379060A1 (en) 2001-01-25
PL352711A1 (en) 2003-09-08
ATE317869T1 (de) 2006-03-15
EP1198490B1 (en) 2006-02-15
KR20070086708A (ko) 2007-08-27
AU769517B2 (en) 2004-01-29
PT1198490E (pt) 2006-06-30
KR100758158B1 (ko) 2007-09-12
EP1198490A1 (en) 2002-04-24
HK1048484A1 (en) 2003-04-04
WO2001005873A1 (en) 2001-01-25
DK1198490T3 (da) 2006-06-19
DE60026030D1 (de) 2006-04-20
ES2255501T3 (es) 2006-07-01
HUP0202177A2 (hu) 2002-12-28
AU5930300A (en) 2001-02-05
NO20020175D0 (no) 2002-01-14
ZA200200303B (en) 2003-03-26
NO20020175L (no) 2002-01-14

Similar Documents

Publication Publication Date Title
BR0012443A (pt) Lipolìmero neutro e composições de lipossoma contendo o mesmo
ATE383169T1 (de) Komponente und zusammensetzungen zur verabreichung von wirkstoffen
FI971776A (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
TR199800436A2 (xx) Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�.
TR199902606T2 (xx) Farnesil transferaz� engelleyici kinazolinonlar.
IL140710A0 (en) Pulmonary delivery of active agents
TR200102603T2 (tr) Antitümör aktiviteye sahip olan kamptotesin türevleri
ATE178067T1 (de) Camptothecinderivate
TR200103186T2 (tr) MEK enzimlerinin inhibitörleri olarak kinolin türevleri
BG103793A (en) COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS
RU2002100651A (ru) Липосомальная композиция, нейтральный липополимер и способ увеличения времени циркуляции липосомы
TNSN98075A1 (fr) Analogues peptidiques de la lh-rh, leur utilisation et les compositions pharmaceutiques les contenant.
TR199802289A2 (xx) Fosfonasit-ikame etmi� benzazepinon-n-asetikasit t�revleri.
TR199902383T2 (xx) Yeni pirimidin t�revleri ve bunlar�n haz�rlanmas� i�in proses.
EP2082740A3 (en) Use of imidazole derivatives as MDR modulators
EE05719B1 (et) L-karnitiini või alkanoüül-L-karnitiinide estrite kasutamine katioonsete lipiididena farmakoloogiliselt aktiivsete komponentide intratsellulaarseks kohaletoimetamiseks
TR200101663T2 (tr) Pro-kollajen c-proteinaz inhibitörleri
TR200103624T2 (tr) Amof bileşikler ve bunların farmasötik bileşimleri.
HUP0002683A2 (hu) Terápiás anyagok sejtekhez való eljuttatásának fokozására szolgáló készítmények és módszerek
BR0001201A (pt) Composto ( poli ) tia-alcinóicos, composição cosmética, utilização de uma composição cosmética, utilização de um composto e composição farmacêutica
TR200101493T2 (tr) Eletriptan hidrobromid monohidrat
DE69928646D1 (de) Derivate des streptogramins, ihre herstellung und sie enthaltende zubereitungen
BR9811954A (pt) ácidos 3-aril-succinamido-hidroxâmicos, processos para sua produção e preparações farmacêuticas contendo estas substâncias
WO1999018917A3 (de) Mittel zum färben von keratinhaltigen fasern mit einem gehalt an dehydroascorbinsäure
TR200001721T2 (tr) Metalloprotein inhibitörleri olarak azulen hidroksamik asit türevleri.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 47/34, A61K 9/127, A61K 47/42, C08G 65/239

Ipc: A61K 47/34 (2009.01), A61K 9/127 (2009.01), A61K 4

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM ART. 8O, 10( VIII ), 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.